Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal
Arcus Biosciences touted its Merck-rivaling kidney cancer treatment results Tuesday, and shares rose, reversing a premarket dive.
The post Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal appeared first on Investor's Business Daily .